Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 15/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 14/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 14/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 2/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745311 | 0.98 | GNAO1 (0.43) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL25754972 | 0.94 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL21180109 | 0.94 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL20417319 | 0.94 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL18609539 | 0.94 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL19803483 | 0.94 | GNAO1 (0.38) | GNAO1GNAI3GNAI1EPHX1SLC6A2 | |
| SCHEMBL24246865 | 0.94 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL24435761 | 0.94 | GNAO1 (0.46) | GNAO1GNAI3GNAI1EPHX1CCR2 | |
| SCHEMBL22224480 | 0.94 | GNAO1 (0.42) | GNAO1GNAI3GNAI1EPHX1SLC6A2 | |
| SCHEMBL22224479 | 0.92 | GNAO1 (0.44) | GNAO1GNAI3GNAI1EPHX1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | GNAO1 1449/4885GNAI3 409/4885GNAI1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.